Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.32	$2.59	$1.11 ▼ $10.54	$45.21M	1.51	443,870 shs	119,687 shs
BFRG Bullfrog AI	$1.21 -1.6%	$1.43	$1.17 ▼ $4.84	$12.20M	0.47	507,091 shs	80,617 shs
LTRN Lantern Pharma	$4.08 +0.5%	$4.02	$2.55 ▼ $6.12	$44.06M	1.6	138,544 shs	71,423 shs
VTVT vTv Therapeutics	$15.53 -1.7%	$15.46	$12.62 ▼ $26.99	$49.53M	0.57	1,363 shs	3,029 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-1.69%	-2.10%	-12.27%	-0.43%	-73.37%
BFRG Bullfrog AI	-2.38%	+2.50%	-15.17%	-26.84%	-47.88%
LTRN Lantern Pharma	+0.25%	-3.10%	+4.91%	+34.88%	-2.40%
VTVT vTv Therapeutics	-1.23%	+5.08%	+9.00%	+1.58%	+5.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.9714 of 5 stars	3.3	3.0	0.6	1.7	0.6
BFRG Bullfrog AI	0.8629 of 5 stars	0.0	3.0	2.7	2.5	0.0
LTRN Lantern Pharma	2.7311 of 5 stars	3.5	3.0	3.3	0.8	0.6
VTVT vTv Therapeutics	2.0993 of 5 stars	3.5	3.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	672.53% Upside
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
LTRN Lantern Pharma	3.00	Buy	$25.00	509.76% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	128.30% Upside

Current Analyst Ratings Breakdown

Latest BFRG, VTVT, LTRN, and ANVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.94 per share	N/A
BFRG Bullfrog AI	$60K	199.92	N/A	N/A	$0.22 per share	5.41
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.16 per share	N/A
VTVT vTv Therapeutics	$1.02M	48.63	N/A	N/A	$0.75 per share	20.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.04	N/A	N/A	N/A	N/A	-206.01%	-158.26%	11/14/2025 (Estimated)
BFRG Bullfrog AI	-$6.99M	-$0.76	N/A	∞	N/A	N/A	-195.35%	-162.37%	N/A
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	11/6/2025 (Estimated)
VTVT vTv Therapeutics	-$18.46M	-$3.12	N/A	∞	N/A	N/A	-179.75%	-55.91%	11/11/2025 (Estimated)

Latest BFRG, VTVT, LTRN, and ANVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRG Bullfrog AI	N/A	-$0.15	N/A	-$0.15	N/A	$0.03 million
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
8/12/2025	Q2 2025	VTVT vTv Therapeutics	-$0.85	-$0.92	-$0.07	-$0.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	7.65	7.65
BFRG Bullfrog AI	N/A	3.97	3.97
LTRN Lantern Pharma	N/A	3.52	3.52
VTVT vTv Therapeutics	N/A	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
BFRG Bullfrog AI	0.96%
LTRN Lantern Pharma	28.62%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
BFRG Bullfrog AI	24.72%
LTRN Lantern Pharma	8.50%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
BFRG Bullfrog AI	4	10.08 million	7.59 million	Not Optionable
LTRN Lantern Pharma	20	10.80 million	9.88 million	Optionable
VTVT vTv Therapeutics	9	3.19 million	3.06 million	Not Optionable

BFRG, VTVT, LTRN, and ANVS Headlines

Recent News About These Companies

vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | finanznachrichten.de

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | finanznachrichten.de

vTv Therapeutics Receives Notice of Allowance for Cadisegliatin Patent, Strengthening Protection for Type 1 Diabetes Treatment

August 11, 2025 | quiverquant.comQ

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | globenewswire.com

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

August 7, 2025 | globenewswire.com

vTv Therapeutics Inc (VTVT) Share Chat - Investing.com UK

June 29, 2025 | uk.investing.com

VTVT - vTv Therapeutics Inc Class A Chart - Morningstar

June 27, 2025 | morningstar.comM

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.comT

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.comQ

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.orgN

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG, VTVT, LTRN, and ANVS Company Descriptions

Annovis Bio NYSE:ANVS

$2.32 0.00 (0.00%)

Closing price 03:58 PM Eastern

Extended Trading

$2.32 0.00 (0.00%)

As of 06:00 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Bullfrog AI NASDAQ:BFRG

$1.21 -0.02 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.01 (+0.41%)

As of 05:43 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Lantern Pharma NASDAQ:LTRN

$4.08 +0.02 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.09 +0.01 (+0.25%)

As of 04:10 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

vTv Therapeutics NASDAQ:VTVT

$15.52 -0.27 (-1.68%)

Closing price 03:57 PM Eastern

Extended Trading

$15.52 0.00 (0.00%)

As of 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time